Skip to main content

Table 1 Description of studies providing data on FEV1 and SGRQ, dyspnoea (TDI), or exacerbations for long-acting bronchodilators

From: Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review

Study Duration, (months)* Number randomised (by treatment) Age, (years) Male, (%) Smoking history, (pack years) FEV1 % predicted Outcomes reported
        SGRQ total SGRQ domains Number with ≥ 1 exacerbation TDI
Aaron 2007 [11] 12 304 (T 156, T + S 148) 65.9 (8.6) 56 50.3 (27.6) 41.7 (13.3) Yes No Yes Yes
Baumgartner 2007 [12] 3 428 (A 141, S 144, Pl 143) 62.9 (9.0) 58 NR 40.8 (12.7) Yes Yes Yes Yes
Beeh 2006 [32] 3 1639 (T 1236, Pl 403) 62.2 (8.7) 76 35.8 (19.5) 45.5 (14.9) No No Yes No
Boyd 1997 [33] 4 456 (S 229, Pl 227) 61.5 79 NR NR No No Yes Yes
Briggs 2005 [34] 3 653 (T 328, S 325) 64.4 (6.3) 67 55.9 (28.8) 37.7 (12.1) No No Yes No
Brusasco 2003 [13] 6 1207 (T 402, S 405, Pl 400) 64.2 (8.4) 76 43.8 (23.2) 38.5 (11.8) Yes No Yes Yes
Calverley 2003 [14] 12 733 (S 372, Pl 361) 63.3 (8.6) 72 43.6 (22.2) 44.3 (13.8) Yes No No No
Calverley 2007 [15] 12 6184 (S 1521, Pl 1524) 65.0 (8.2) 76 49.0 (27.3) 43.9 (12.5) Yes No No No
Campbell 2005 [16] 6 442 (F 225, Pl 217) 60 68 37 53.8 Yes No Yes No
Casaburi 2000 [35] 3 470 (T 279, Pl 191) 65.2 (8.8) 65 62.9 (32.0) 39.0 (13.9) No No Yes No
Casaburi 2002 [17] 12 921 (T 550, Pl 371) 65.0 (9.0) 65 61.0 (30.5) 38.6 (13.9) Yes Yes Yes No
Chan 2007[18] 12 913 (T 608, Pl 305) 66.8 (8.8) 60 50.4 (23.9) 39.4 (13.5) Yes Yes Yes No
Chapman 2002 [19] 6 408 (S 201, Pl 207) NR 64 38 45 Yes Yes Yes No
Covelli 2005 [36] 3 196 (T 100, Pl 96) 64.6 (9.0) 58 65.5 (33.4) 39.4 (13.4) No No Yes No
Dahl 2001 [20] 6 392 (F 192, Pl 200) 63.5 (8.4) 77 41.8 45.0 (12.7) Yes Yes Yes No
Donohue 2002 [21] 6 623 (T 209, S 213, Pl 201) 64.9 (7.9) 75 47.0 (25.0) 42.3 (9.3) Yes Yes Yes Yes
Donohue 2008 [37] 12 793 (Af 528, S 265) 64.2 (8.8) 59 NR 38.0 (13.1) No No Yes No
Dusser 2006 [38] 12 1010 (T 500, Pl 510) 64.8 (9.3) 88 NR 47.9 (12.7) No No Yes No
Freeman 2007 [39] 3 395 (T 200, Pl 195) 64.9 (9.1) 54 37.4 (17.3) 48.9 (10.6) No No Yes No
Gross 2008 [22] 3 351 (F 123, Pl 114) 62.7 (8.9) 58 NR 44.5 (12.1) Yes Yes Yes No
Johansson 2008 [40] 3 224 (T 107, Pl 117) 61.5 (8.3) 48 31.5 (12.1) 73.4 (12.6) No No Yes No
Jones 1997 [23] 3 189 (S 94, Pl 95) 62.5 (8.0) 79 NR 46.0 (15.0) Yes No No No
Mahler 1999 [41] 3 411 (S 135, I 133, Pl 143) 63.5 (8.5) 74 60.2 (32.5) 40.0 No No Yes Yes
Moita 2008 [42] 3 311 (T 147, Pl 164) 64.3 (8.6) 95 55.0 (23.6) 41.4 (14.1) No No Yes No
Niewoehner 2005 [43] 6 1829 (T 914, Pl 915) 67.9 (8.6) 99 68.4 (36.0) 35.6 (12.6) No No Yes No
Rennard 2009 [24] 12 976 (F 495, Pl 481) 63.0 (9.1) 65 NR 40.1 (11.7) Yes Yes No No
Rossi 2002 [25] 12 645 (F 214, Pl 220) 62.7 83 NR 47.7 Yes Yes Yes No
Sepracor inc. NCT00250679 2009 [26] 6 296 (F 147, Af 149) 64.7 (8.4) 61 NR 41.0 (12.6) Yes No Yes Yes
Stahl 2001 [5] 3 121 (F 61, Pl 60) 64 52 NR 33.3 Yes No No No
Stockley 2006 [27] 12 726 (S 316, Pl 318) 62.4 (9.2) 67 39.7 (21.6) 46.0 (14.3) Yes Yes No No
Tashkin 2008 [28] 6 584 (F 284, Pl 300) 63.4 (9.6) 67 NR 40.4 (12.5) Yes Yes No No
Tashkin 2008 [29] 12 5993 (T 2987, Pl 3006) 64.5 (8.5) 75 48.7 (28.0) 39.4 (12.0) Yes No Yes No
Tashkin 2009 [30] 3 255 (T + F 124, T 131) 63.8 (8.6) 66 NR NR Yes Yes Yes Yes
Tonnel 2008 [31] 9 554 (T 266, Pl 288) 64.2 (9.9) 86 43.7 (21.9) 46.8 (12.8) Yes Yes Yes No
van Noord 2000 [44] 3 97 (S 47, Pl 50) 74.0 (6.5) 88 NR 40.3 (10.7) No No Yes No
Vogelmeier 2008 [45] 6 847 (F 210, T 221, F + T 207, Pl 209) 62.6 (8.8) 78 38.0 (19.7) 51.2 (9.9) No No Yes No
  1. Data are mean (SD) unless otherwise stated. *time point used in analyses
  2. Af: arformoterol, F: formoterol, FEV1: forced expiratory volume in one second, NR: not reported, Pl: placebo, S: salmeterol, SGRQ: St George's Respiratory Questionnaire, T: tiotropium, TDI: Transition Dyspnea Index